GENFIT S.A. - American Depositary Shares (GNFT)
Frequently Asked Questions About GENFIT S.A. - American Depositary Shares (GNFT)
Has GENFIT received any significant regulatory approvals?
Yes, GENFIT has received various regulatory approvals for its research programs and has advanced its product candidates through clinical trials. Notably, the company has also engaged with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to seek guidance on trial design and regulatory pathways for its innovative treatments, including elafibranor for NASH.
How can investors stay informed about GENFIT's progress?
Investors can stay informed about GENFIT's progress through regular updates via the company's investor relations website, press releases, and financial reports. Additionally, participating in earnings calls and attending industry conferences will provide stakeholders with insights into the company’s developments, strategic initiatives, and overall performance in the biopharmaceutical landscape.
How does GENFIT approach research and development?
GENFIT approaches research and development through a combination of rigorous scientific inquiry, clinical trials, and collaborations with other institutions and companies. The company utilizes its proprietary technologies and deep expertise in the field to identify and develop potential therapeutic candidates, while following a strategic plan to address key areas with significant unmet medical needs.
How does GENFIT maintain its competitive edge?
GENFIT maintains its competitive edge by focusing on innovation in drug development, investing in advanced research technologies, and fostering strong collaborations within the scientific community. By prioritizing areas of high unmet medical need and pursuing a robust clinical pipeline, the company aims to stay at the forefront of biopharmaceutical advancements.
On which stock exchange are GENFIT's ADS listed?
GENFIT's American Depositary Shares (ADS) are listed on the Nasdaq stock exchange under the ticker symbol GNFT. Listing on Nasdaq allows the company to attract a wider range of investors and enhances its visibility in the global financial markets, particularly in the United States.
What are American Depositary Shares (ADS)?
American Depositary Shares (ADS) are negotiable securities that represent shares of a foreign company's stock. Each ADS represents a specific number of shares and enables U.S. investors to buy and trade shares of foreign companies on American exchanges, providing increased market access and liquidity while simplifying investment in international firms.
What are GENFIT's core values?
GENFIT's core values emphasize innovation, integrity, patient-focus, and collaboration. The company is committed to advancing scientific discovery while maintaining ethical standards, fostering a corporate culture that prioritizes the needs of patients, and encouraging teamwork and partnerships within the global scientific and medical community.
What clinical trials is GENFIT currently conducting?
GENFIT is currently conducting several clinical trials for its lead product candidate, elafibranor, and other compounds in its pipeline. These trials aim to evaluate the efficacy and safety of its treatments in various patient populations, including those suffering from NASH and related metabolic disorders, as well as exploring other potential therapeutic avenues.
What collaborations has GENFIT engaged in?
GENFIT has engaged in various strategic collaborations with academic institutions and industry partners to enhance its research capabilities and streamline drug development processes. These collaborations focus on sharing knowledge, resources, and technological advancements, ultimately aimed at accelerating the discovery and development of therapies for liver diseases.
What does GENFIT S.A. do?
GENFIT S.A. is a biopharmaceutical company dedicated to developing innovative therapeutic solutions for metabolic and fibrotic diseases, notably Non-Alcoholic Steatohepatitis (NASH) and other liver-related disorders. The company focuses on discovering and developing drug candidates, particularly for conditions related to liver health and metabolic dysfunction, harnessing advanced science and technology to address unmet medical needs.
What is GENFIT's financial outlook?
GENFIT's financial outlook involves an assessment of its revenue-generating potential through product commercialization, ongoing clinical trials, and strategic partnerships. The company closely monitors its financial health through funding initiatives including public and private investments, grants, and collaborations that support its R&D efforts while ensuring sustainability and growth within the market.
What is GENFIT's lead product candidate?
GENFIT's lead product candidate is elafibranor, which is being developed for the treatment of Non-Alcoholic Steatohepatitis (NASH). Elafibranor targets key pathways involved in liver inflammation and insulin resistance, with the aim of reversing the progression of NASH and ultimately improving liver health, making it a critical focus for the company's clinical development programs.
What is NASH?
NASH, or Non-Alcoholic Steatohepatitis, is a progressive liver disease characterized by the accumulation of fat in the liver, inflammation, and liver cell damage, occurring in individuals who consume little to no alcohol. It is associated with obesity, diabetes, and metabolic syndrome, and can lead to more severe liver problems such as cirrhosis or liver cancer if left untreated.
What is the company's stance on corporate social responsibility?
GENFIT is committed to corporate social responsibility, aiming to positively impact society and the communities in which it operates. This encompasses ethical business practices, environmental sustainability, and active engagement in health-related initiatives, reinforcing its dedication to improving global health outcomes and supporting initiatives that promote well-being.
What role does GENFIT play in the life sciences community?
GENFIT plays a significant role in the life sciences community by driving forward research and development efforts in the fields of metabolic diseases and liver health. The company collaborates with academic institutions, other biotech firms, and healthcare professionals to foster innovation, share knowledge, and ultimately improve patient outcomes through novel therapeutics and solutions.
When was GENFIT S.A. founded?
GENFIT S.A. was founded in 1999 in Lille, France. Since its inception, the company has expanded its focus and capabilities in the field of drug discovery and development, particularly in areas dealing with liver diseases and metabolic conditions, solidifying its position in the biotechnology and pharmaceutical landscape.
Where is GENFIT S.A. headquartered?
GENFIT S.A. is headquartered in Lille, France. This location serves as the cornerstone for its operations, giving the company access to the vibrant European biotech ecosystem, while also maintaining a global perspective that includes operations and research collaborations across various international markets.
Who are GENFIT's key competitors?
GENFIT faces competition from other biopharmaceutical and biotech companies focusing on liver diseases and metabolic disorders. Key competitors include companies like Intercept Pharmaceuticals and Gilead Sciences that are also developing treatments for NASH and related liver conditions, creating an intensely competitive landscape as these firms race to bring effective therapies to market.
What is the current price of GENFIT S.A. - American Depositary Shares?
The current price of GENFIT S.A. - American Depositary Shares is 3.360
When was GENFIT S.A. - American Depositary Shares last traded?
The last trade of GENFIT S.A. - American Depositary Shares was at 1:25 pm EDT on April 4th, 2025
What is the market capitalization of GENFIT S.A. - American Depositary Shares?
The market capitalization of GENFIT S.A. - American Depositary Shares is 130.65M
How many shares of GENFIT S.A. - American Depositary Shares are outstanding?
GENFIT S.A. - American Depositary Shares has 38.89M shares outstanding.